Variation in the Cox-2 Gene May Modify the Effect of Alendronate on Vertebral Fracture Prevention
Authors:
- A. Hossein-NezhadAHA. Hossein-Nezhad
- K. MirzaeiKMK. Mirzaei
- 1 September 2010
- journal article
- research article
- Published by SAGE Publications in European Journal of Inflammation
- Vol. 8 (3) , 143-149
Abstract
Bisphosphonates such as alendronate, which are potent specific inhibitors of osteoclast-mediated bone resorption, are widely used for treatment of postmenopausal osteoporosis as well as other diseases related to bone remodeling. We evaluated whether the reportedly functional PTGS2 (prostaglandin-endoperoxide synthase 2/cyclooxygenase [COX] 2) genotypes influence the efficacy of alendronate on vertebral fracture prevention. Sixty postmenopausal osteoporotic women participated in this interventional study. The extent of vertebral fracture was evaluated in all participants before and after intervention using X-ray imaging. Alendronate (10mg/day), calcium (1gr/day) and vitamin D (400mg/day) were given to participants for 2 years. Laboratory measurements included circulating crosslaps, osteocalcin, PTH, osteoporotegrin, RANKL, vitamin D, TNF-α, IL-6, IL-1 levels. Hip and spine BMD (bone mass density) were measured using DEXA. Genotyping for cox-2 gene SNP (−765G/C) was performed using PCR- RFLP method. Genotype frequency of homozygous major allele (GG), heterozygous (GC) and homozygous minor allele (CC) were 61.7%, 33.3% and 5% respectively. Evaluation of vertebral fracture before alendronate therapy in participants demonstrated no significant difference between carriers of G and C alleles, although the difference appeared near to significant after alendronate therapy at the end of 2 years. Serum PTH level and L2-L4 BMD were significantly different between subjects with different alleles. Moreover, IL-1 had prominently higher concentration in C allele carries. Furthermore, there was a significant difference in terms of the extent of vertebral fracture between two allelic groups after two years of treatment. Since bone remodeling process has been proved to be affected by inflammatory factors; it appears that variation in COX-2 genotypes may influence alendronate efficacy in fracture prevention among postmenopausal osteoporotic women.Keywords
This publication has 18 references indexed in Scilit:
- Low concentration of lipopolysaccharide acts on MC3T3‐E1 osteoblasts and induces proliferation via the COX‐2‐independent NFκB pathwayCell Biochemistry and Function, 2009
- Giant Osteoclast Formation and Long-Term Oral Bisphosphonate TherapyNew England Journal of Medicine, 2009
- Three Years of Alendronate Treatment Results in Similar Levels of Vertebral Microdamage as After One Year of TreatmentJournal of Bone and Mineral Research, 2007
- Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronateBone, 2006
- Prostacyclin Synthase and Arachidonate 5-Lipoxygenase Polymorphisms and Risk of Colorectal PolypsCancer Epidemiology, Biomarkers & Prevention, 2006
- Quantitative Structure−Activity Relationships for γδ T Cell Activation by BisphosphonatesJournal of Medicinal Chemistry, 2003
- Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repairJournal of Clinical Investigation, 2002
- Cyclo-Oxygenase 2 Function Is Essential for Bone Fracture HealingJournal of Bone and Mineral Research, 2002
- Transcriptional Regulation of the Cyclooxygenase-2 Gene by Diverse Ligands in Murine OsteoblastsBiochemical and Biophysical Research Communications, 1999
- Aging and matrix microdamage accumulation in human compact boneBone, 1995